Autoantigen presentation by splenic dendritic cells is required for RBC-specific autoimmunity.

These data suggest that if erythrocyte T-cell tolerance fails, DCs are capable of initiating autoimmune responses. As such, targeting DCs may be a fruitful strategy for AIHA therapies.